Kappa-Gaffa: OspA activates HIV-1 and other viruses
Mort Zuckerman
lPick...@cdc.gov, Durlan...@yale.edu, Aa...@columbia.edu,
gary_w...@nymc.edu, scientifi...@ostp.gov,
pkru...@princeton.edu, Stanle...@fiu.edu,
emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, Northern Auto Parts, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, criminal...@usdoj.gov,
karla.d...@usdoj.gov, christophe...@usdoj.gov,
richar...@yale.edu, harol...@yale.edu, james.p...@yale.edu,
inq...@aldf.com, ly...@idsociety.org, meganm...@theatlantic.com
Subject: Kappa-Gaffa: OspA activates HIV-1 and other viruses
Date: Jul 11, 2010 10:40 AM
TLR2 agonist OspA activates HIV-1:
http://www.ncbi.nlm.nih.gov/pubmed/20610663
TLR2 and NFkappa:
http://www.ncbi.nlm.nih.gov/pubmed?term=tlr2[All%20Fields]%20AND%20nf[All%20Fields]%20AND%20kappa[All%20Fields]&cmd=DetailsSearch
TLR2 agonist OspA downrgulates TLR2
expression and MHC molecules (no antibodies
are produced):
http://www.ncbi.nlm.nih.gov/pubmed/20511710
http://www.jimmunol.org/cgi/content/full/167/2/910
Now check out the tard-ass brainiac-wannabee lawyers/science writers:
http://www.post-trib.com/lifestyles/2479140,jstossel0711.article
"More importantly, innovators dump potentially life-saving inventions.
Companies that started work on a safer asbestos substitute, an AIDS
vaccine and a Lyme disease vaccine gave up the research because any
work in those areas risked stirring up the lawyers. The liability risk
was too great."
OspA/TLR2-agonism is the key to
nearly all chronic diseases and is
the very meaning of ACQUIRED IMMUNE
DEFICIENCY outcomes (or Great Imitators).
The so-called lawyers had nothing to do
the end of "Lyme Disease." Sheller sued
over OspA over Steere's claim that Lyme was
just a hypersensitivity reaction to OspA-
the hyperbinding of OspA to HLA molecules.
Now even Allen Steere says no such
thing happens:
http://www.ncbi.nlm.nih.gov/pubmed/20506317
Steere says chronic Lyme is a result of
immune suppression.
CONCLUSION: See only ActionLyme if you want
sci-med investment advice.
Hilarious.
Kathleen M. Dickson
http://www.actionlyme.org
http://www.relapsingfever.org
KMDickson